VERALOX Therapeutics-preview

Veralox

VERALOX Therapeutics

Private

Frederick, MarylandHealthcare & Life Scienceshttps://veralox.com

Last Round

VC Round

Jun 20, 2023

Total Funding Raised

$22.32M

Company Overview

VERALOX Therapeutics is a clinical-stage biotechnology company developing first-in-class therapeutics that target the 12-lipoxygenase (12-LOX) pathway for the treatment of immuno-inflammatory diseases such as Heparin-Induced Thrombocytopenia (HIT) and Type 1 Diabetes (T1D).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B2C

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

12-LOX inhibitorHeparin-Induced ThrombocytopeniaHITsmall molecule drug discoveryclinical-stage biotechfirst-in-class drugsplatelet activation inhibitorthrombosis treatmentautoimmune disease therapeuticsType 1 Diabetes treatmentT1DcGAS inhibitorsOrphan Drug designationFast Track designation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

VERALOX Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

VERALOX Therapeutics Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
VC Round	Jun 20, 2023
Series A	Jun 16, 2021
Seed	Sep 5, 2019
Grant	Sep 7, 2018

View all Funding Rounds

Key People

Founding team and executive leadership

Matthew Boxer

Co-Founder And COO

Founding Team

VERALOX Therapeutics Investors

Notable investors and investment history

Investor	Rounds
A. M. Pappas & Associates	VC Round
Hatteras Venture Partners	VC Round, Series A
TEDCO	Seed, Series A
Genesys Capital	Series A, VC Round
Alexandria Venture Investments	Series A
University System of Maryland Momentum Fund	Seed, Series A
Sanofi Ventures	Series A, VC Round, Seed

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Dec 11, 2025
Acquired 12-LOX assets for HIT treatment.

View all signals

VERALOX Therapeutics Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

VERALOX Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about VERALOX Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersFrederick, Maryland

Employee Range9

Year Founded2017

Last FundingJun 20, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.